Team Fox Chase Cancer Center from a prior BCAN Walk to End Bladder Cancer
Join me & Team Fox Chase in the 2026 Walk to End Bladder Cancer. We are dedicated to changing the outlook of bladder cancer & supporting the Bladder Cancer Advocacy Network (BCAN) with the amazing things they do.
—Sat April 25
Info here:
nam10.safelinks.protection.outlook.com?url=https%3A...
@uretericbud.bsky.social @erplimackmd.bsky.social @urocorrea.bsky.social @foxchaseoaa.bsky.social
Team Fox Chase Cancer Center from a prior BCAN Walk to End Bladder Cancer
Join me & Team Fox Chase in the 2026 Walk to End Bladder Cancer. We are dedicated to changing the outlook of bladder cancer & supporting the Bladder Cancer Advocacy Network (BCAN) with the amazing things they do.
—Sat April 25
Info here:
nam10.safelinks.protection.outlook.com?url=https%3A...
Twelve exceptional Fox Chase GU experts are participating in the Together Facing GU Cancers event on 4/23/26. Register here https://www.foxchase.org/events/together-facing-genitourinary-cancers-2026?utm_source=X&utm_medium=Social&utm_campaign=Community-Events
Highlighting an upcoming educational workshop at
Philly’s Cancer Center #FoxChaseCancerCenter
—A chance for Q/A with many of our leading faculty
Thursday April 23
Registration here: www.foxchase.org/events/toget...
Flashback to our 2019 interview day, our fellow grads from 2022: (L) Dr. Jared Schober, now at U Nebraska (R) Dr Kevin Ginzburg, now at Wayne State
Getting ready to host Fox Chase Cancer Center SUO fellowship interviews. Excited to be back in-person for the first time since these superstars!
#UroEd #UroSome
@ascocancer.bsky.social #GU26 Day 3–it’s kidney day!
K-M curves of ctDNA result
K-M curves of ctDNA as dynamic biomarker
ctDNA predicts extravesical not local disease
Summary of conclusions
Dr. Ghatalia giving talk of LBA at general session
The protocol schema for ph2 single-arm RETAIN-2 trial
@ascocancer.bsky.social A major late breaking abstract from Fox Chase: ctDNA informing outcome and prognosis for MIBC post-NAT and is a key parameter for risk-adapted management
An amazing presentation by Dr. Ghatalia, worth reviewing the recording again
#blcsm
Recurrence following EV/P v Cis/Gem
OS results for EV/P v Cis/Gem
#GU26 @ascocancer.bsky.social
Keynote-B15 results—significantly improves RFS/OS compared to Gem/Cis
#blcsm
Galsky at the podium at GU ASCO Day 2
Keynote-B15 Protocol schema
Protocol pathway and results
#GU26 @ascocancer.bsky.social
Starting off with practice changing presentation of Keynote-B15:
Galsky reporting the unprecedented response surpassing Cis-Platin for NeoAdjuvant Treatment, this will cement EV/P as SOC for all MIBC
#blcsm
#ASCO #GU26
Barocas highlights idea of
Regret=Expectations - Outcome
Probably more accurate to be in the opposite order:
Regret=Outcome - Expectations
➡️when expectations are higher than outcome, regret is a net negative result
Figure of functional change after treatment, between open RP and 2-D RT. https://www.nejm.org/doi/full/10.1056/NEJMoa1209978
#ASCO #GU26
Session on localized #ProstateCancer
Dr. Ron Chen highlights functional impacts, comparing RP v RT
*Emphasizes for PCOS that was much less sophisticated radiation
I would add that was much less sophisticated surgery (open RRP) #pcsm
#ASCO #GU26
You can tell the make up for the meeting’s attendees at the afternoon #prostatecancer general session on localized disease
Lots of empty seats (not a criticism of the speakers)
—Dr. Barocas shows slides on anatomy, not Kaplan-Meyer curves—Not much of a draw if you are a med onc 🤷🏻♂️
#ASCO #GU26
Re: comment from the audience:
I appreciate the patient advocate sharing he has a new #prostatecancer diagnosis stemming from his getting a #PSA spurred by the Super Bowl Ad!
#ScreeningSavesLives
www.relaxitsabloodtest.com?site=GK10010...
#pcsm
🔜 #GU26 @ascocancer.bsky.social
How to approach a vast meeting w/so much data?
Look beyond data that repackages known truths but do NOT really advance understanding
Common examples:
1. Less cancer is better than more cancer
2. Responders do better
3. More treatments vs. less improves PFS
#ASCO #GU26
My comment on POSEIDON
Looking at ADT w/PORT (=post-op RT)
—for adding ADT, it recs apply for PSA >0.5, not PSA <0.5
**As surgeons we shouldn’t be seeing that high a PSA BCR, should get PORT before such “high” levels.
And there is prob benefit for ADT in BCR with very short PSA DT
Can confirm
A Cornell urology residency alum presenting the Keynote address for Philly Urologic (PUS)
Two old guys who trained together in urology starting at the end of the last century
Great to see Jaspeet Sandhu @mskcancercenter.bsky.social in town to give the Philadelphia Urologic Society B.A. Thomas lecture—a leader in urology cancer survivorship. Has it really been over 25 yrs since we were at The Brady? #CornellMafia
#UroSoMe #UroSky
Screenshot of the article. Two more royal colleges join the X exodus—why medical leaders are refusing to tweet The RCP and the RCGP are stepping back from Elon Musk’s social media platform, citing abuse and hatred. Three other medical organisations have left, and two are reviewing their activity. Chris Stokel-Walker reports
Second page. Excerpt here: Grok, the AI image generator, brings concerns to a head Once Musk had taken over Twitter and then renamed it X in 2023, he reshaped it by removing guardrails and firing the trust and safety staff who were meant to monitor users’ behaviour and the content posted, to help keep the app a pleasant place. As a result, abuse and harmful content thrived. Things came to a head over Christmas 2025 when users began weaponising X’s AI image generator, Grok, to harass women by posting nude or scantily clothed images of them. Ofcom, the UK’s communications regulator, opened an investigation into the platform after the technology minister, Liz Kendall, raised concerns in parliament. Matt Navarra, a social media expert, says, “I think the royal colleges, operating in tightly regulated sectors like healthcare, can’t afford to be seen sharing space with platforms that are under investigation for failing to prevent harm. And that’s a compliance risk, not just a PR risk.”
From the @bmj.com this week - some commentary on the exodus of medical leaders from X that used to be Twitter.
It’s sad, but I think it’s the right thing to move away from that platform.
#MedSky
Link here:
www.bmj.com/content/392/...
Image of post from that other site giving details on upcoming information open house hosted by the PDs of 3 leading GURS training programs.
FYI—this unique opportunity is next week, to meet PDs of the premier GURS fellowship programs in one setting.
Feb 5–
One Zoom – Don't miss it!
Register: tinyurl.com/Gursopenhouse
@SocietyGURS @urorecon @jsimhan @TempleUrology @FCUroOnc @caseurology #GURS #UrologyFellowship
#UroEd
Hey, let’s get you over here. Maybe double post here and that other place and see if we can increase the traffic to a critical mass. #UroSoMe
Reposting from that other site, the announcement about FCCC virtual open house on our SUO fellowship
Inviting interested candidates to the FCCC Uro Onc fellowship virtual open house
Link here to register:
forms.office.com/pages/respon...
#SurgEd #FCCCProud #PhillysCancerCenter
Announcing an open house information session about the Urology Residency at the Fox Chase-Temple Urologic Institute
Jon Stewart responded to CBS bowing down to Trump and canceling Colbert
Challenge Cup U-18 Finals
Warming up at WSFS fields
Countdown to last game of high school career
